Novocure announced today that the last patient has been
enrolled in the PANOVA trial, a phase 2 pilot trial testing Tumor
Treating Fields (TTFields) plus chemotherapy in 40 patients with
advanced pancreatic cancer. The final data collection date will be six
months after the last patient in.
The prospective, single-arm study includes two cohorts of 20 patients
with advanced pancreatic cancer whose tumors could not be removed
surgically and who had not received prior chemotherapy or radiation
therapy. Novocure presented data from the first cohort of the trial at
the American Society of Clinical Oncology 2016 Gastrointestinal Cancers
Symposium in January 2016.
Data from the first cohort demonstrated the safety of the combined
treatment, and also suggest improved survival and response rate among
patients who received TTFields therapy with gemcitabine compared to a
historical control of patients who received gemcitabine alone. PANOVA
patients who received TTFields therapy plus first-line gemcitabine
experienced a median progression free survival of 8.3 months compared to
3.7 months for a historical control of gemcitabine alone, and a median
overall survival of 14.9 months compared to 6.7 months for a historical
control. Median one-year survival was 55 percent compared to 22 percent
for a historical control.
Novocure accelerated planning for
a phase 3 clinical trial in pancreatic cancer after obtaining results
for the first cohort of PANOVA.
No comments:
Post a Comment